Recherchiere Firmenbekanntmachungen und finanzielle Kennzahlen
EU-Förderung (4.637.478 €): Die künstliche Bauchspeicheldrüse bei Kindern im Alter von 1 bis 7 Jahren mit Typ-1-Diabetes Hor15.12.2016 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Auf einen Blick
Text
Die künstliche Bauchspeicheldrüse bei Kindern im Alter von 1 bis 7 Jahren mit Typ-1-Diabetes
TYPE 1 DIABETES is one of the most COMMON CHRONIC diseases in children with a RAPID increase in number of cases particularly in young children. Type 1 diabetes is associated with LIFE-LONG dependency on insulin administration. POOR glucose control leads to diabetes COMPLICATIONS, e.g. eye, heart, kidney disease, including BRAIN changes in young children. Episodes of VERY LOW glucose levels may be life threatening and are a major complication. The ARTIFICIAL PANCREAS addresses the problem of LOW and HIGH glucose levels by delivering insulin BELOW and ABOVE pre-set amounts according to real-time sensor GLUCOSE levels, combining glucose SENSOR, insulin PUMP, and CONTROL ALGORITHM. The Artificial pancreas promises to TRANSFORM management of type 1 diabetes but EVIDENCE supporting its use during FREE LIVING in YOUNG CHILDREN is MISSING. The project evaluates the biomedical, psychosocial, and cost effectiveness of NOVEL INDIVIDUALISED artificial pancreas in young children aged 1 to 7 years with type 1 diabetes. Following a PILOT (n=24), in the MAIN study (n=94) half of the participants (n=47) will be treated over 12 MONTHS by the ARTIFICIAL PANCREAS and the other half (n=47) by STATE-OF-THE-ART PREDICTIVE LOW GLUCOSE MANAGEMENT insulin pump therapy. Each treatment will last ONE YEAR. QUALITY OF LIFE will be assessed and semi-structured INTERVIEWS conducted to understand the impact on daily life. HEALTH TECHNOLOGY ASSESSMENT will support reimbursement. The project will OPTIMISE artificial pancreas and SPEARHEAD SYSTEM-WIDE improvements in health care quality and health outcomes in YOUNG CHILDERN with TYPE 1 DIABETES who live with the disease LONGEST. By IMPROVING THERAPEUTIC OUTCOMES, the project will CHANGE clinical practice and INFLUENCE national and international treatment guidelines making the artificial pancreas WIDELY ACCEPTABLE as the state-of-art treatment modality in young children.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| Centre Hospitalier DE Luxembourg | 330.275 € |
| 182.844 € | |
| 0,00 € | |
| Medizinische Universitaet Wien | 386.525 € |
| 397.441 € | |
| 374.025 € | |
| The Chancellor Masters and Scholars of the University of Cambridge | 1.874.079 € |
| 330.275 € | |
| The University of Edinburgh | 325.459 € |
| UNIVERSITAET LEIPZIG | 342.775 € |
| Vyoo Agency | 93.780 € |
Quelle: https://cordis.europa.eu/project/id/731560
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.
Die Visualisierungen zu "Centre Hospitalier DE Luxembourg - EU-Förderung (4.637.478 €): Die künstliche Bauchspeicheldrüse bei Kindern im Alter von 1 bis 7 Jahren mit Typ-1-Diabetes"
werden von
North Data
zur Weiterverwendung unter einer
Creative Commons Lizenz
zur Verfügung gestellt.
